title: PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke.
abstract: BACKGROUND
  Plasma markers for stroke could be useful in diagnosis and prognosis and in prediction of response of stroke patients to therapy. PARK7 and nucleoside diphosphate kinase A (NDKA) are increased in human postmortem cerebrospinal fluid (CSF), a model of global brain insult, suggesting that measurement in CSF and, more importantly, in plasma may be useful as a biomarker of stroke.
  
  
  METHODS
  We used ELISA to measure PARK7 and NDKA in plasma in 3 independent European and North American retrospective studies encompassing a total of 622 stroke patients and 165 control individuals.
  
  
  RESULTS
  Increases in both biomarkers were highly significant, with sensitivities of 54%-91% for PARK7 and 70%-90% for NDKA and specificities of 80%-97% for PARK7 and 90%-97% for NDKA. The concentrations of both biomarkers increased within 3 h of stroke onset.
  
  
  CONCLUSIONS
  PARK7 and NDKA may be useful plasma biomarkers for the early diagnosis of stroke. In addition, this study demonstrated the utility of analysis of postmortem CSF proteins as a first step in the discovery of plasma markers of ischemic brain injury.
authors.affiliation: Biomedical Proteomics Research Group, Department of Structural Biology and Bioinformatics, Medical and University Center, Geneva, Switzerland. laure.allard@medecine.unige.ch
authors.forename: Laure
authors.initials: L
authors.lastname: Allard
authors.forename: Pierre R
authors.initials: PR
authors.lastname: Burkhard
authors.forename: Pierre
authors.initials: P
authors.lastname: Lescuyer
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Burgess
authors.forename: Nadia
authors.initials: N
authors.lastname: Walter
authors.forename: Denis F
authors.initials: DF
authors.lastname: Hochstrasser
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Sanchez
mesh_terms: D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005060:Europe; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D054778:NM23 Nucleoside Diphosphate Kinases; D009656:North America; D009701:Nucleoside-Diphosphate Kinase / Q000097:blood* / Q000134:cerebrospinal fluid; D015513:Oncogene Proteins / Q000097:blood* / Q000134:cerebrospinal fluid; D010949:Plasma; D000071617:Protein Deglycase DJ-1; D020543:Proteome / Q000032:analysis; D012680:Sensitivity and Specificity; D020521:Stroke / Q000097:blood / Q000134:cerebrospinal fluid / Q000175:diagnosis*
chemical_list: D015415:Biomarkers; D047908:Intracellular Signaling Peptides and Proteins; D054778:NM23 Nucleoside Diphosphate Kinases; D015513:Oncogene Proteins; D020543:Proteome; D009701:Nucleoside-Diphosphate Kinase; C105131:PARK7 protein, human; D000071617:Protein Deglycase DJ-1